Reckitt Benckiser Group plc and Adams Respiratory Therapeutics have entered into a definitive agreement under which Reckitt Benckiser will tender for the acquisition of Adams for $60 per share in cash ($2.3 billion).
At a recent shareholders meeting, P&G President and Chief Executive A. G. Lafley said, "We are now focused on delivering a full decade of industry-leading top and bottom line growth.
